英文名 | KO-539 | ||
---|---|---|---|
CAS号 | 2134675-36-6 | 分子量 | 717.87 |
产品编号 | NC00526 | MDL | |
外观与形状 | 熔点 | ||
纯度 | 97% | 沸点 | |
分子式 | C33H42F3N9O2S2 | 闪点 |
KO-539 is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need; In preclinical models, KO-539 inhibits the KMT2A/MLL protein complex and has downstream effects on HOXA9/MEIS1 expression. KO-539 has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML.
CAS No. | 2140-72-9 |
产品编号 | NC00723 |
纯度 | 97% |
CAS No. | 2140-76-3 |
产品编号 | NC00722 |
纯度 | 97% |
CAS No. | 2140-71-8 |
产品编号 | NC00720 |
纯度 | 97% |
CAS No. | 603130-12-7 |
产品编号 | NC00704 |
纯度 |
CAS No. | 2134675-36-6 |
产品编号 | NC00526 |
纯度 | 97% |